XML 59 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Revenue Recognized under Agreement with GSK (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended	3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2006 Astra Zeneca	Jun. 30, 2013 Astra Zeneca	Jun. 30, 2012 Astra Zeneca	Jun. 30, 2013 Astra Zeneca	Jun. 30, 2012 Astra Zeneca	Dec. 31, 2008 Astra Zeneca	Jun. 30, 2013 National Institute Of Allergy And Infectious Diseases	Jun. 30, 2012 National Institute Of Allergy And Infectious Diseases	Jun. 30, 2013 National Institute Of Allergy And Infectious Diseases	Jun. 30, 2012 National Institute Of Allergy And Infectious Diseases	Dec. 31, 2008 Glaxo, Smith, Kline	Jun. 30, 2013 Glaxo, Smith, Kline	Jun. 30, 2012 Glaxo, Smith, Kline	Jun. 30, 2013 Glaxo, Smith, Kline	Jun. 30, 2012 Glaxo, Smith, Kline	Dec. 31, 2011 Glaxo, Smith, Kline	Jun. 30, 2013 National Institutes of Health	Jun. 30, 2012 National Institutes of Health	Jun. 30, 2013 National Institutes of Health	Jun. 30, 2012 National Institutes of Health
Product Information [Line Items]
Initial payment					$ 10,000	$ 180	$ 180	$ 360	$ 360						$ 10,000	$ 357	$ 357	$ 714	$ 714
Performance of research activities						819	1,086	1,165	1,478	4,500										12,000
Total	3,392	2,684	5,477	5,034		999	1,266	1,525	1,838
Grant revenue	$ 1,395	$ 882	$ 2,155	$ 1,969							$ 1,062	$ 750	$ 1,660	$ 1,740							$ 333	$ 132	$ 495	$ 229

X

- Definition

Revenue from collaboration agreement.

+ References

No definition available.

+ Details

Name:	dvax_CollaborationRevenue
Namespace Prefix:	dvax_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_ProductInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RevenueFromGrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration